Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Safety and efficacy of chemotherapy for patients with unresectable pancreatic cancer concomitant with collagen disease: A multicenter retrospective observational study.
Authors
Hiroyuki Asama
Department of Gastroenterology, Fukushima Medical University, Fukushima-Shi, Japan
Hiroyuki Asama , Hiroyuki Okuyama , Yasuyuki Kawamoto , Kumiko Umemoto , Takuo Yamai , Satoshi Kobayashi , Masafumi Watanabe , Yasuo Hamamoto , Takaaki Furukawa , Yohei Kitano , Masayo Motoya , Yuko Suzuki , Akihiro Ohba , Kazuo Watanabe , Naohiro Okano , Kazuhiko Shioji , Noritoshi Kobayashi , Hiroshi Imaoka , Takeshi Terashima , Makoto Ueno
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 650)
DOI
10.1200/JCO.2024.42.3_suppl.650
Abstract #
650
Poster Bd #
K19
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Evaluation of a cell viability assay based on cultures of CTICs to identify treatment options in third-line pancreatic cancer.
First Author: Mark Ricigliano
Poster
2016 Gastrointestinal Cancers Symposium
FOLFIRINOX and gemcitabine/nab-paclitaxel efficacy in the treatment of locally advanced unresectable pancreatic adenocarcinoma.
First Author: Filip Bednar
Poster
2014 ASCO Annual Meeting
Patterns of chemotherapy (CT) use in a population-based US-wide cohort of patients (pts) with metastatic pancreatic cancer (MPC).
First Author: Thomas Adam Abrams
Poster
2024 ASCO Gastrointestinal Cancers Symposium
DIsCOvER: A multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to investigate the efficacy and safety of dronabinol in the improvement of chemotherapy-induced and tumor-related symptoms in patients with locally advanced or metastatic pancreas cancer during first-line chemotherapy.
First Author: Felix Keil